Iambic Therapeutics, Inc. - 8-K Filing

Iambic Therapeutics reports Q3 2026 collaboration revenue of $11.4M and pro-forma cash position of $455M following IPO and AbbVie payments. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $IAM

Read the full article at SEC EDGAR

More Regulatory news